Aileron Therapeutics Inc (ALRN) Stock: Navigating the Market Volatility

2d ago, source: newsheater

The stock of Aileron Therapeutics Inc (ALRN) has seen a -9.17% decrease in the past week, with a -4.12% drop in the past month, and a 19.15% flourish in the past quarter. The volatility ratio for the ...

Aileron Therapeutics Inc ALRN

4d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Aileron Therapeutics sharestarget doubled by Ladenburg Thalmann

1d ago, source: Investing

On Thursday, Ladenburg Thalmann demonstrated confidence in Aileron Therapeutics Inc (NASDAQ:ALRN) shares, with a significant increase in the company's stock price target. The firm doubled the ...

Aileron Therapeutics gets grant for modified CAV-1 peptides for lung infection and injury treatment

4d ago, source: Pharmaceutical Technology

Discover the groundbreaking patent by Aileron Therapeutics for modified caveolin-1 peptides to treat lung infections and fibrosis. Learn about the unique peptide sequence and its potential ...

Aileron Therapeutics, Inc.

3y ago, source: CNN

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and ...

Aileron Therapeutics Inc ALRN

16d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Aileron Therapeutics, Inc. (ALRN)

1y ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Aileron Therapeutics Inc.

3y ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...